KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target
Open Access
- 28 August 2026
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 514
Abstract
Purpose: This review aims to provide an updated overview of Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations in colorectal carcinoma (CRC), focusing on their role in tumorigenesis, prognostic implications, and recent advances in targeted therapy. Major findings: KRAS mutations occur in approximately 40% of colorectal cancers and play a central role in tumour initiation and progression through constitutive activation of MAPK pathways. Clinically, KRAS mutations are well established as predictors of resistance to anti-EGFR therapy. Increasing evidence also supports their role as prognostic biomarkers, with KRAS-mutant tumours associated with increased recurrence risk and reduced survival, including in patients undergoing hepatic metastasectomy. Therapeutically, recent advances, most notably KRAS G12C inhibitors and combination strategies targeting upstream or parallel pathways, have expanded treatment options, although efficacy varies across KRAS mutation subtypes. Conclusions: KRAS mutations have important implications for the behaviour, prognosis, and management of colorectal cancer. Integrating KRAS mutational status into clinical decision-making may enable more personalised prognostication and treatment strategies. Continued research is required to broaden effective targeted therapies for the diverse spectrum of KRAS-mutant disease.Keywords
This publication has 91 references indexed in Scilit:
- Disrupted molecular glue complex drives RAS inhibitor resistanceCell, 2026
- Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancerCancer Cell, 2025
- A first-in-class EGFR-directed KRAS G12V selective inhibitorCancer Cell, 2025
- Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studyAnnals of Oncology, 2024
- Wnt/β-catenin signaling in colorectal cancer: Is therapeutic targeting even possible?Biochimie, 2022
- Molecular epidemiology and diagnostics of KRAS mutations in human cancerCancer and Metastasis Reviews, 2020
- RAS Proteins and Their Regulators in Human DiseaseCell, 2017
- Molecular pathological classification of colorectal cancerVirchows Archiv, 2016
- KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastasesCancer, 2014
- A genetic model for colorectal tumorigenesisCell, 1990